Healthcare / BiotechnologyNasdaqGS
$2.39
-0.12 (-4.78%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-86.2M · quality 64.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
25/100
D
Piotroski
1/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$173M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-172.3%
↓Gross Margin
N/A
•Debt/Equity
0.44
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2020–2025 · 5 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
0.95x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-121.3M · FCF $-115.6M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Net Income | $-121.3M | $-121.3M | $-102.3M | $-52.4M | $-42.9M | $-100.6M | $-7.3M |
| EBITDA | $-116.9M | $-116.9M | $-98.1M | $-51.6M | $-42.7M | — | — |
| EPS | -2.00 | -2.00 | -1.71 | -1.08 | -1.06 | -5.02 | — |
| Balance Sheet | |||||||
| Debt/Equity | 0.44 | 0.44 | 0.16 | 0.11 | 0.00 | — | — |
| Current Ratio | 4.55 | 4.55 | — | — | — | — | — |
| Cash Flow | |||||||
| Free Cash Flow | $-115.6M | $-115.6M | $-86.2M | $-43.1M | $-35.3M | — | — |
| Returns | |||||||
| ROE | -172.3% | -172.3% | -56.3% | -19.6% | -22.7% | -44.7% | 39.4% |
| Valuation | |||||||
| P/B | 2.06 | 2.06 | 0.63 | 0.73 | 1.13 | — | — |
| Growth & Yield | |||||||
| EPS Growth | -17.0% | -17.0% | -58.3% | -1.9% | — | — | — |
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+139.0%
Start / end P/E
n/dx → n/dx
EPS bridge
-1.71 → -2.00
Residual
+139.0%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.